Fairness in Precision Medicine
By Kadija Ferryman and Mikaela Pitcan,
Data & Society
| 02. 26. 2018
Fairness in Precision Medicine is the first report to deeply examine the potential forbiased and discriminatory outcomes in the emerging field of “precision medicine,” or “the effort to collect, integrate, and analyze multiple sources of data in order to develop individualized insights about health and disease.” Supported by the Robert Wood Johnson Foundation, the report is the first in a new series of research projects at Data & Society focused on the future of health data.
The authors–Data & Society Postdoctoral Scholar Dr. Kadija Ferryman and Data & Society Researcher Mikaela Pitcan–present insights on emergent tensions in the field arising from extensive qualitative interviews with biomedical researchers, bioethicists, technologists, and patient advocates.
Among the report’s key findings is a potential for bias and discrimination both in datasets (through a lack of cohort diversity; technical processes of data collection and cleaning; or the specific incorporation of electronic health record data) and in outcomes(through too much focus on individual responsibility for health; or the marginalization of population groups with lower health literacy or in less resourced areas)...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...